36. Epidermolysis bullosa
147 clinical trials,   170 drugs   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04491604 (ClinicalTrials.gov) | August 2020 | 22/7/2020 | The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). | A Phase III Double Blinded, Placebo-Controlled, Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) | Dystrophic Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis Bullosa;Dominant Dystrophic Epidermolysis Bullosa | Biological: Topical Beremagene Geperpavec;Other: Placebo | Krystal Biotech, Inc. | NULL | Recruiting | 6 Months | N/A | All | 30 | Phase 3 | United States |
2 | NCT03536143 (ClinicalTrials.gov) | May 7, 2018 | 20/4/2018 | Topical Beremagene Geperpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa | A Phase II Study of Beremagene Geperpavec (KB103), a Non-Integrating, Replication-Incompetent Herpes Simplex Virus 1 (HSV-1) Vector Expressing the Human Collagen VII (COL7) Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) | Dystrophic Epidermolysis Bullosa | Biological: Topical beremagene geperpavec | Krystal Biotech, Inc. | NULL | Active, not recruiting | 5 Years | N/A | All | 4 | Phase 2 | United States |